

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (previously presented) A pharmaceutical composition for topical administration, said composition consisting essentially of:
  - at least 5% by weight, based on the total weight of the composition, of minoxidil or a pharmaceutically acceptable salt thereof;
  - an acid in an amount to substantially completely solubilize the minoxidil or a pharmaceutically acceptable salt thereof, wherein the acid is a mineral acid selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, or an organic acid selected from the group consisting of citric acid, acetic acid, succinic acid, maleic acid, benzoic acid, lactic acid and mixtures thereof;
  - a solvent selected from water and/or a lower alcohol;
  - a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols present in an amount of less than approximately 10% by weight;
  - wherein the final product of the pharmaceutical composition is selected from the group consisting of a solution, lotion, ointment, mousse, a foam that breaks with shear, spray, aerosol, shampoo, conditioner, gel, cream and paste.
2. (previously presented) The pharmaceutical composition according to Claim 1, wherein the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less.
3. (previously presented) The pharmaceutical composition according to Claim 1, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of from approximately 5 to 25% by weight, based on the total weight of the pharmaceutical composition.

4. (previously presented) The pharmaceutical composition according to Claim 3, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of approximately 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.

5. (canceled)

6. (previously presented) The pharmaceutical composition according to Claim 2, wherein the acid provides to the composition an apparent pH in the range of approximately 5.0 to 7.0.

7. (canceled)

8. (previously presented) The pharmaceutical composition according to Claim 2, wherein the acid is acetic acid or lactic acid.

9. (canceled)

10. (previously presented) The pharmaceutical composition according to Claim 1, wherein the co-solvent is benzyl alcohol.

11. (previously presented) The pharmaceutical composition according to Claim 10, wherein the benzyl alcohol is present in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent.

12. (previously presented) The pharmaceutical composition according to Claim 1, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the composition.

13. (currently amended) The pharmaceutical composition according to Claim 1, wherein the co-solvent is ~~an alkylene glycol~~ a polyhydric alcohol.

14. (currently amended) The pharmaceutical composition according to Claim 13, wherein the alkylene glycol co-solvent is selected from one or more of the group consisting of glycerol, 1,3-butylene glycol or propylene glycol.

15. (previously presented) The pharmaceutical composition according to Claim 1, wherein the acid is present at a level that provides at least 0.01 Normal acid.

16. (previously presented) The pharmaceutical composition according to Claim 1, wherein the acid is present in an amount equal to or greater than the amount of the minoxidil in Normal amounts.

17. (canceled)

18. (canceled)

19. (previously presented) The pharmaceutical composition according to Claim 1, wherein the minoxidil salt is minoxidil acetate or minoxidil lactate.

20. (previously presented) The pharmaceutical composition according to Claim 1, wherein

the minoxidil or a minoxidil acid salt is present in an amount of approximately 5 to 12% by weight, based on the total weight of the composition.

21. (previously presented) A method for the treatment of hair loss and related indications in humans, comprising the steps of:

providing a pharmaceutical composition, consisting essentially of at least 5% by weight, based on the total weight of the composition, of minoxidil or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilize the minoxidil or a pharmaceutically acceptable salt thereof, wherein the acid is a mineral acid selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, or an

organic acid selected from the group consisting of citric acid, acetic acid, succinic acid, maleic acid, benzoic acid, lactic acid and mixtures thereof;

a solvent selected from water and/or a lower alcohol;

a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols is present in an amount of less than approximately 10% by weight; and

applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical composition.

22. (canceled)

23. (previously presented) The method according to Claim 21, wherein the minoxidil salt is minoxidil acetate or minoxidil lactate.

24. (previously presented) The method according to Claim 21, wherein the minoxidil or a minoxidil acid salt is present in an amount of approximately 5 to 12% by weight, based on the total weight of the composition.

25. (canceled)

26. (previously presented) The pharmaceutical composition according to claim 1, wherein the lower alcohol is ethanol.

27. (previously presented) The pharmaceutical composition according to claim 1, wherein the solvent is water and ethanol.

28. (previously presented) The pharmaceutical composition according to claim 27, wherein the ratio of water to ethanol is approximately 9:1 to 1:9 by volume.

29. (previously presented) The pharmaceutical composition according to claim 27, wherein the ratio of water to ethanol is approximately 1:1 to 1:3 by volume.

30. (previously presented) An aerosol pharmaceutical composition for topical administration, said pharmaceutical composition consisting essentially of:

approximately 5% or greater by weight of minoxidil or a pharmaceutically acceptable salt thereof;

an acid in an amount effective to substantially completely solubilize the minoxidil or pharmaceutically acceptable salt thereof, wherein the acid is a mineral acid selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, or an organic acid selected from the group consisting of citric acid, acetic acid, succinic acid, maleic acid, benzoic acid, lactic acid and mixtures thereof;

a solvent selected from water and/or a lower alcohol;

a higher alcohol and a stabilizer;

a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols present in an amount of less than approximately 10% by weight;

an antioxidant, and a propellant, wherein the final product of the aerosol formulation is a foam or a mousse.

31. (previously presented) The pharmaceutical composition according to claim 30, wherein the co-solvent is a polyhydric alcohol.

32. (previously presented) The pharmaceutical composition according to claim 31, wherein the co-solvent is selected from glycerol, 1,3-butylene glycol or propylene glycol.

33. (previously presented) The pharmaceutical composition according to claim 32, wherein the co-solvent is glycerol.

34. (previously presented) The pharmaceutical composition according to claim 32, wherein the co-solvent is 1,3-butylene glycol.

35. (previously presented) The pharmaceutical composition according to claim 32, wherein the co-solvent is propylene glycol.

36. (previously presented) The pharmaceutical composition according to claim 30, wherein the acid is lactic acid.

37. (previously presented) The pharmaceutical composition according to claim 30, wherein the higher alcohol is a member selected from the group consisting of cetyl alcohol, stearyl alcohol and combinations thereof.

38. (previously presented) The pharmaceutical composition according to claim 30, wherein the stabilizer is Polysorbate 60.

39. (previously presented) The pharmaceutical composition according to claim 30, wherein the composition is homogeneous.

40. (previously presented) The pharmaceutical composition according to claim 30, wherein the lower alcohol is ethanol.

41. (previously presented) The pharmaceutical composition according to claim 30, wherein the solvent is water and ethanol.

42. (previously presented) The pharmaceutical composition according to claim 41, wherein the ratio of water to ethanol is approximately 9:1 to 1:9 by volume.

43. (previously presented) The pharmaceutical composition according to claim 41, wherein the ratio of water to ethanol is approximately 1:1 to 1:3 by volume.

44. (previously presented) A method for the treatment of hair loss and related indications in humans, comprising applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical composition according to claim 30, to treat hair loss and related indications.

45. (previously presented) A pharmaceutical gel for topical administration, said composition consisting essentially of:

at least 5% by weight, based on the total weight of the composition, of minoxidil or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilize the minoxidil or a pharmaceutically acceptable salt thereof, wherein the acid is a mineral acid selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, or an organic acid selected from the group consisting of citric acid, acetic acid, succinic acid, maleic acid, benzoic acid, lactic acid and mixtures thereof;

a solvent selected from water and/or a lower alcohol;

a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols present in an amount of less than approximately 10% by weight; and

a gelling agent or thickener.

46. (previously presented) The pharmaceutical gel according to claim 45, wherein said gelling agent or thickener is a cellulose derivative.

47. (previously presented) The pharmaceutical gel according to claim 46, wherein said gelling agent or thickener is a hydroxy propyl cellulose.

48. (previously presented) The pharmaceutical gel according to claim 45, wherein the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less.

49. (previously presented) The pharmaceutical gel according to claim 45, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of from approximately 5 to 25% by weight, based on the total weight of the pharmaceutical composition.

50. (previously presented) The pharmaceutical gel according to claim 49, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of approximately 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.

51. (previously presented) The pharmaceutical gel according to claim 48, wherein the acid provides to the composition an apparent pH in the range of approximately 5.0 to 7.0.

52. (previously presented) The pharmaceutical gel according to claim 45, wherein the acid is acetic or lactic acid.

53. (previously presented) The pharmaceutical gel according to claim 45, wherein the lower alcohol is ethanol.

54. (previously presented) The pharmaceutical gel according to claim 45, wherein the solvent is water and ethanol.

55. (previously presented) The pharmaceutical gel according to claim 54, wherein the ratio of water to ethanol is approximately 9:1 to 1:9 by volume.

56. (previously presented) The pharmaceutical gel according to claim 54, wherein the ratio of water to ethanol is approximately 1:1 to 1:3 by volume.

57. (previously presented) The pharmaceutical gel according to claim 45, wherein the co-solvent is benzyl alcohol.



58. (previously presented) The pharmaceutical gel according to claim 57, wherein the benzyl alcohol is present in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent.

59. (previously presented) The pharmaceutical gel according to claim 45, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the composition.

60. (currently amended) The pharmaceutical gel according to claim 45, wherein the co-solvent is ~~an alkylene glycol~~ a polyhydric alcohol.

61. (currently amended) The pharmaceutical gel according to claim 60, wherein the alkylene glycol co-solvent is selected from one or more of the group consisting of glycerol, 1,3-butylene glycol or propylene glycol.

62. (previously presented) The pharmaceutical gel according to claim 45, wherein the acid is present at a level that provides at least 0.01 Normal acid.

63. (previously presented) The pharmaceutical gel according to claim 45, wherein the acid is present in an amount equal to or greater than the amount of the minoxidil in Normal amounts.

64. (previously presented) The pharmaceutical gel according to claim 45, wherein the minoxidil salt is minoxidil acetate or minoxidil lactate.

65. (previously presented) A method for the treatment of hair loss and related indications in humans, comprising applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical gel according to claim 45, to treat hair loss and related indications.

66. (previously presented) A topical minoxidil lotion, said topical minoxidil lotion consisting essentially of:

at least 5% by weight, based on the total weight of the composition, of minoxidil or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilize the minoxidil or a pharmaceutically acceptable salt thereof, wherein the acid is a mineral acid selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, or an organic acid selected from the group consisting of citric acid, acetic acid, succinic acid, maleic acid, benzoic acid, lactic acid and mixtures thereof;

a solvent selected from water and/or a lower alcohol;

a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols present in an amount of less than approximately 10% by weight;

one or more oil components; and

a stabilizer.

67. (previously presented) The topical minoxidil lotion according to claim 66, wherein the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less.

68. (previously presented) The topical minoxidil lotion according to claim 66, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of from approximately 5 to 25% by weight, based on the total weight of the pharmaceutical composition.

69. (previously presented) The topical minoxidil lotion according to claim 68, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of approximately 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.

70. (previously presented) The topical minoxidil lotion according to claim 67, wherein the acid provides to the composition an apparent pH in the range of approximately 5.0 to 7.0.

71. (previously presented) The topical minoxidil lotion according to claim 66, wherein the acid is lactic acid.

72. (previously presented) The topical minoxidil lotion according to claim 66, wherein the acid is acetic acid.

73. (previously presented) The topical minoxidil lotion according to claim 66, wherein the lower alcohol is ethanol.

74. (previously presented) The topical minoxidil lotion according to claim 66, wherein the solvent is water and ethanol.

75. (previously presented) The topical minoxidil lotion according to claim 74, wherein the ratio of water to ethanol is approximately 9:1 to 1:9 by volume.

76. (previously presented) The topical minoxidil lotion according to claim 74, wherein the ratio of water to ethanol is approximately 1:1 to 1:3 by volume.

77. (previously presented) The topical minoxidil lotion according to claim 66, wherein the co-solvent is benzyl alcohol.

78. (previously presented) The topical minoxidil lotion according to claim 77, wherein the benzyl alcohol is present in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent.

79. (previously presented) The topical minoxidil lotion according to claim 66, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the composition.

80. (currently amended) The topical minoxidil lotion according to claim 66, wherein the co-solvent is ~~an alkylene glycol~~ a polyhydric alcohol.

81. (currently amended) The topical minoxidil lotion according to claim 80, wherein the ~~alkylene glycol~~ co-solvent is selected from one or more of the group consisting of glycerol, 1,3-butylene glycol or propylene glycol.

82. (currently amended) The topical minoxidil lotion according to claim 81, wherein the ~~alkylene glycol~~ co-solvent is propylene glycol.

83. (previously presented) The topical minoxidil lotion according to claim 66, wherein the acid is present at a level that provides at least 0.01 Normal acid.

84. (previously presented) The topical minoxidil lotion according to claim 66, wherein the acid is present in an amount equal to or greater than the amount of the minoxidil in Normal amounts.

85. (previously presented) The topical minoxidil lotion according to claim 66, wherein the minoxidil salt is minoxidil acetate or minoxidil lactate.

86. (previously presented) The topical minoxidil lotion according to claim 66, wherein the oil component is one or more members selected from the group consisting of olive oil, squalane, fluid paraffin, isopropyl myristate, a higher fatty acid, and a higher alcohol.

87. (previously presented) The topical minoxidil lotion according to claim 66, wherein the stabilizer is one or more members selected from the group consisting of Polysorbate 60, and polyoxyethylene lauryl alcohol.

88. (previously presented) A method for the treatment of hair loss and related indications in humans, comprising applying topically to the human scalp a therapeutically or prophylactically effective amount of the lotion according to claim 66, to treat hair loss and related indications.

**89.** (previously presented) A topical minoxidil solution, said topical minoxidil solution consisting essentially of:

at least 5% by weight, based on the total weight of the composition, of minoxidil or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilize the minoxidil or a pharmaceutically acceptable salt thereof, wherein the acid is a mineral acid selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, or an organic acid selected from the group consisting of citric acid, acetic acid, succinic acid, maleic acid, benzoic acid, lactic acid and mixtures thereof;

a solvent selected from water and/or a lower alcohol; and

a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols present in an amount of less than approximately 10% by weight.

**90.** (previously presented) The topical minoxidil solution according to claim **89**, wherein the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less.

**91.** (previously presented) The topical minoxidil solution according to claim **89**, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of from approximately 5 to 25% by weight, based on the total weight of the pharmaceutical composition.

**92.** (previously presented) The topical minoxidil solution according to claim **91**, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of approximately 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.

**93.** (previously presented) The topical minoxidil solution according to claim **90**, wherein the acid provides to the composition an apparent pH in the range of approximately 5.0 to 7.0.

94. (previously presented) The topical minoxidil solution according to claim 89, wherein the acid is acetic or lactic acid.

95. (previously presented) The topical minoxidil solution according to claim 89, wherein the acid is lactic acid.

96. (previously presented) The topical minoxidil solution according to claim 89, wherein the acid is acetic acid.

97. (previously presented) The topical minoxidil solution according to claim 89, wherein the lower alcohol is ethanol.

98. (previously presented) The topical minoxidil solution according to claim 89, wherein the solvent is water and ethanol.

99. (previously presented) The topical minoxidil solution according to claim 98, wherein the ratio of water to ethanol is approximately 9:1 to 1:9 by volume.

100. (previously presented) The topical minoxidil solution according to claim 98, wherein the ratio of water to ethanol is approximately 1:1 to 1:3 by volume.

101. (previously presented) The topical minoxidil solution according to claim 89, wherein the co-solvent is benzyl alcohol.

102. (previously presented) The topical minoxidil solution according to claim 101, wherein the benzyl alcohol is present in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent.

103. (previously presented) The topical minoxidil solution according to claim 89, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the composition.

104. (currently amended) The topical minoxidil solution according to claim 89, wherein the co-solvent is ~~an alkylene glycol~~ a polyhydric alcohol.

105. (currently amended) The topical minoxidil solution according to claim 104, wherein the ~~alkylene glycol~~ co-solvent is selected from one or more of the group consisting of glycerol, 1,3-butylene glycol or propylene glycol.

106. (currently amended) The topical minoxidil solution according to claim 105, wherein the ~~alkylene glycol~~ co-solvent is propylene glycol.

107. (previously presented) The topical minoxidil solution according to claim 89, wherein the acid is present at a level that provides at least 0.01 Normal acid.

108. (previously presented) The topical minoxidil solution according to claim 89, wherein the acid is present in an amount equal to or greater than the amount of the minoxidil in Normal amounts.

109. (previously presented) The topical minoxidil solution according to claim 89, wherein the minoxidil salt is minoxidil acetate or minoxidil lactate.

110. (previously presented) The topical minoxidil solution according to claim 89, further comprising one or more members selected from the group consisting of Polysorbate 60 and polyoxyethylene lauryl alcohol.

111. (previously presented) A method for the treatment of hair loss and related indications in humans, comprising applying topically to the human scalp a therapeutically or

prophylactically effective amount of the topical minoxidil solution according to claim 89, to treat hair loss and related indications.

112. (previously presented) A pharmaceutical composition for topical administration, said composition consisting essentially of:

at least 5% by weight, based on the total weight of the composition, of minoxidil or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilize the minoxidil or a pharmaceutically acceptable salt thereof, wherein the acid is a mineral acid selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, or an organic acid selected from the group consisting of citric acid, acetic acid, succinic acid, maleic acid, benzoic acid, lactic acid and mixtures thereof;

a solvent selected from water and/or a lower alcohol;

a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols present in an amount of less than approximately 10% by weight; and

a penetration agent;

wherein the final product of the pharmaceutical composition is selected from the group consisting of a solution, lotion, ointment, mousse, a foam that breaks with shear, spray, aerosol, shampoo, conditioner, gel, cream and paste.

113. (previously presented) The pharmaceutical composition according to claim 112, wherein the penetrating agent is selected from the group consisting of an alcohol, an amine, a carboxylic acid, an ester, an azone, N-methyl pyrrolidone, a bile salt and urea.

114. (previously presented) The pharmaceutical composition according to claim 113, wherein the penetrating agent is selected from the group consisting of dodecanol alcohol and oleyl alcohol.



115. (previously presented) The pharmaceutical composition according to claim 113, wherein the penetrating agent is selected from the group consisting of isopropyl amine, diisopropyl amine, triethyl amine, triethanol amine, diisopropanol amine and ethylene diamine.

116. (previously presented) The pharmaceutical composition according to claim 113, wherein the penetrating agent is selected from the group consisting of oleic acid, linoleic acid and linolenic acid.

117. (previously presented) The pharmaceutical composition according to claim 113, wherein the penetrating agent is selected from the group consisting of dibutyl sebacate, dibutyl phthalate, butyl benzoate and ethyl caprate.

118. (previously presented) The pharmaceutical composition according to claim 112, wherein the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less.

119. (previously presented) The pharmaceutical composition according to claim 112, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of from approximately 5 to 25% by weight, based on the total weight of the pharmaceutical composition.

120. (previously presented) The pharmaceutical composition according to claim 119, wherein the minoxidil or pharmaceutically acceptable salt thereof is present in an amount of approximately 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.

121. (previously presented) The pharmaceutical composition according to claim 118, wherein the acid provides to the composition an apparent pH in the range of approximately 5.0 to 7.0.

**122.** (previously presented) The pharmaceutical composition according to claim **118**, wherein the acid is acetic or lactic acid.

**123.** (previously presented) The pharmaceutical composition according to claim **122**, wherein the acid is lactic acid.

**124.** (previously presented) The pharmaceutical composition according to claim **122**, wherein the acid is acetic acid.

**125.** (previously presented) The pharmaceutical composition according to claim **112**, wherein the lower alcohol is ethanol.

**126.** (previously presented) The pharmaceutical composition according to claim **112**, wherein the solvent is water and ethanol.

**127.** (previously presented) The pharmaceutical composition according to claim **126**, wherein the ratio of water to ethanol is approximately 9:1 to 1:9 by volume.

**128.** (previously presented) The pharmaceutical composition according to claim **126**, wherein the ratio of water to ethanol is approximately 1:1 to 1:3 by volume.

**129.** (previously presented) The pharmaceutical composition according to claim **112**, wherein the co-solvent is benzyl alcohol.

**130.** (previously presented) The pharmaceutical composition according to claim **129**, wherein the benzyl alcohol is present in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent.

131. (previously presented) The pharmaceutical composition according to claim 112, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the composition.

132. (currently amended) The pharmaceutical composition according to claim 112, wherein the co-solvent is ~~an alkylene glycol~~ a polyhydric alcohol.

133. (currently amended) The pharmaceutical composition according to claim 132, wherein the ~~alkylene glycol~~ co-solvent is selected from one or more of the group consisting of glycerol, 1,3-butylene glycol or propylene glycol.

134. (currently amended) The pharmaceutical composition according to claim 133, wherein the ~~alkylene glycol~~ co-solvent is propylene glycol.

135. (previously presented) The pharmaceutical composition according to claim 112, wherein the acid is present at a level that provides at least 0.01 Normal acid.

136. (previously presented) The pharmaceutical composition according to claim 112, wherein the acid is present in an amount equal to or greater than the amount of the minoxidil in Normal amounts.

137. (previously presented) The pharmaceutical composition according to claim 112, wherein the minoxidil salt is minoxidil acetate or minoxidil lactate.

138. (previously presented) A method for the treatment of hair loss and related indications in humans, comprising applying topically to the human scalp a therapeutically or prophylactically effective amount of the topical minoxidil solution according to Claim 112, to treat hair loss and related indications.